The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly has agreed to acquire Scorpion Therapeutics ... with shareholders of the private company set to receive up to $2.5 billion in an upfront payment and subsequent payments contingent ...

Eli Lilly LLY-7.51%decrease ... The Indianapolis-based pharmaceutical company said it expects fourth-quarter revenue of $13.5 billion, around $400 below the low end of its last estimated range ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...